
-
Belgian region grapples with forever chemical scandal
-
New-look Australia focused on LA 2028 at swimming worlds
-
China urges global consensus on balancing AI development, security
-
David's century sparks Aussies to T20I clincher over WIndies
-
Death toll rises in Thai-Cambodian clashes despite ceasefire call
-
China prodigy takes on swimming world aged 12
-
UN gathering eyes solution to deadlocked Palestinian question
-
Polls open in Taiwan's high-stakes recall election
-
'Alien' lands at Comic-Con
-
Top footballers afraid to speak out against playing too many games: FIFPro chief
-
Top US Justice official questions Epstein accomplice for 2nd day
-
Cambodia calls for ceasefire with Thailand: envoy to UN
-
Raducanu and Fernandez beat the heat to reach DC Open semis
-
US stocks end at records as markets eye tariff deadline
-
Trump, EU chief to meet Sunday in push for trade deal
-
Fake AI photos of Trump with Epstein flood internet
-
Ponting says 'no reason' why Root cannot top Tendulkar's run record
-
NFL players, employees fined for selling Super Bowl tickets: reports
-
World's smallest snake makes big comeback
-
Trade on agenda as Trump lands in Scotland for diplomacy and golf
-
UN chief blasts 'lack of compassion' for Palestinians in Gaza
-
Trump administration expected to say greenhouse gases aren't harmful
-
Hamilton suffers unprecedented spinning knockout in Belgian GP sprint qualifying
-
European powers urge end to Gaza 'humanitarian catastrophe'
-
Messi, Alba suspended over MLS All-Star no-show: league
-
RB's Permane returns as team boss at Belgian GP two years after sacking
-
Trump says '50/50 chance' of US-EU trade deal
-
Top US Justice official meets with Epstein accomplice for 2nd day
-
Mekies makes retaining Verstappen his Red Bull priority
-
Pogacar exits Alps with Tour stranglehold as Arensman edges white-knuckle win
-
Piastri takes pole for Belgian GP sprint race ahead of Verstappen
-
UK, France, Germany say Gaza 'humanitarian catastrophe must end now'
-
Stock markets mark time as Trump puts EU-US trade deal at 50/50
-
Pogacar exits Alps with Tour stranglehold as Arensman takes stage
-
France defends move to recognise Palestinian state
-
Trade on agenda as Trump heads to Scotland for diplomacy and golf
-
France's top court annuls arrest warrant against Syria's Assad
-
How might Trump's tariffs hurt Brazil?
-
Rubiales forced kiss could drive Spain on in Euro 2025 final: England's Toone
-
Trump says Hamas 'didn't want' Gaza deal as talks break down
-
Tour de France prankster gets eight-month suspended term for crossing finish line
-
Root climbs to second on all-time Test list as England dominate India
-
Stock markets stall as Trump puts EU-US trade deal at 50/50
-
UK starts online checks to stop children accessing harmful content
-
Root up to third on all-time Test list as England dominate India
-
Piastri outpaces Verstappen in opening practice at Belgian GP
-
Cambodian evacuees sheltering in temple pray for end to Thai clashes
-
French car dealer charged over Takata air bag injury
-
Iran meets European powers amid threats of UN sanctions snapback
-
Meta to ban political ads in EU due to bloc's 'unworkable' rules
RBGPF | -1.52% | 73.88 | $ | |
NGG | -0.11% | 72.15 | $ | |
VOD | -0.79% | 11.43 | $ | |
RYCEF | -0.3% | 13.2 | $ | |
GSK | -0.68% | 37.97 | $ | |
SCS | 0.66% | 10.58 | $ | |
SCU | 0% | 12.72 | $ | |
BTI | -0.71% | 52.25 | $ | |
CMSD | 0.17% | 22.89 | $ | |
RELX | -1.86% | 52.73 | $ | |
BCC | 1.94% | 88.14 | $ | |
BP | 0.22% | 32.2 | $ | |
JRI | -0.46% | 13.09 | $ | |
BCE | -0.95% | 24.2 | $ | |
CMSC | 0.24% | 22.485 | $ | |
RIO | -1.16% | 63.1 | $ | |
AZN | -1.4% | 72.66 | $ |

Philips settles US sleep machine cases for $1.1 billion
Dutch medical device maker Philips said Monday it had reached a $1.1 billion deal to settle US lawsuits over faulty sleep machines that have dogged the company.
The company's shares initially soared more than 45 percent in Amsterdam on news of the settlement, which was less onerous than feared by some shareholders, before ending the trading day up just over 28 percent.
Philips has been battling a series of crises since 2021 over its DreamStation machines for sleep apnoea, a disorder in which breathing intermittently stops during sleep.
Millions of devices were recalled over concerns that users were at risk of inhaling pieces of noise-cancelling foam and fears it could potentially cause cancer.
Earlier this year, the company decided to halt new sales in the United States of the machines made by subsidiary Philips Respironics.
Philips said in a statement Monday that it had reached an agreement with the plaintiffs "to resolve the personal injury litigation and the medical monitoring class action to end the uncertainty associated with litigation in the US."
It added that it did not "admit any fault or liability, or that any injuries were caused by Respironics' devices."
The agreement addresses claims filed in US courts and other potential cases, it said.
"Patient safety and quality is our highest priority, and we have taken important steps in further resolving the consequences of the Respironics recall," Philips chief executive Roy Jakobs said in the statement.
"The remediation of the sleep therapy devices for patients is almost complete, and the test results to date show the use of these devices is not expected to result in appreciable harm to health," he said.
"We do regret the concern that patients may have experienced," he said, adding that the settlements were "significant milestones and provide further clarity on the way forward for Philips."
Analysts at Jefferies investment firm said in a note that the settlement was "much milder than feared and shall mark the end of litigation uncertainty".
- 'We can move on' -
Philips, which has had to cut thousands of jobs, posted losses of 463 million euros ($501 million) over the full year in 2023.
It reported on Monday a loss of 824 million euros in the first quarter of this year on sales totalling 4.1 billion euros.
Philips said the settlement payments are expected to take place in 2025 and will be funded through cash flow generation.
The company said it had booked a provision of 982 million euros ($1.05 billion) in the first quarter to cover the settlement.
Philips said it also concluded an agreement with insurers to pay Philips 540 million euros to cover Respironics recall-related claims.
"The three biggest litigation cases that we had are now put behind us," Jakobs said in a conference call.
"We can move on and that's very important," he said, while cautioning that it "doesn't mean that everything is resolved."
Franco-German bank Oddo BHF said that "with the long tail of remaining legal risks being very manageable, we believe the settlement today materially derisks the investment case."
P.Staeheli--VB